Výsledky vyhledávání - "Tjerk W. A. de Bruin"

Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability

Autor: Jennifer E. Hamer-Maansson, Weifeng Tang, Stots Reele, Tjerk W. A. de Bruin, Shamik Parikh

Publikováno v: Clinical Pharmacology in Drug Development. 5:118-130

The pharmacokinetics (PK) of dapagliflozin and metformin administered as fixed-dose combination (FDC) tablets (2.5 mg dapagliflozin/850 mg metformin or 5 mg dapagliflozin/1000 mg metformin) or as separate tablets in healthy subjects were evaluated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::527d4ca32f2b933464a799196641781b
https://doi.org/10.1002/cpdd.220

Zobrazit plný text záznamu

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

Autor: Tjerk W. A. de Bruin, Jennifer Sugg, Shamik Parikh, Lawrence A. Leiter, William T. Cefalu, Ingrid Gause-Nilsson

Publikováno v: Diabetes Care

OBJECTIVE To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4ccd45429573cc0c79a4888c6c6a52
https://doi.org/10.2337/dc14-0315

Zobrazit plný text záznamu

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial

Autor: Andrey V. Susekov, Hong Yang, Mats Kvarnström, Tjerk W. A. de Bruin, Michael H. Davidson, Erik S.G. Stroes

Publikováno v: Journal of clinical lipidology, 12(2), 321-330. Elsevier BV

Adult patients with severe hypertriglyceridemia (SHTG) are at increased risk of developing acute pancreatitis and cardiovascular disease. Omega-3 carboxylic acids (OM3-CA) are approved for treatment as an adjunct to diet to reduce triglyceride (TG) c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92967a01e93f56b0753c30bc93de340
https://pubmed.ncbi.nlm.nih.gov/29289538

Zobrazit plný text záznamu

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

Autor: Agata Ptaszynska, Kristina Johnsson, Shamik Parikh, James F. List, Tjerk W. A. de Bruin, A. Apanovitch

Publikováno v: Drug Safety. 37:815-829

Dapagliflozin reduces hyperglycaemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion. This study determined the overall safety profile of dapagliflozin in T2DM. Safety of dapagliflozin in pooled analyses of ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f471b8a103247bb9ed628e6a53af48bc
https://doi.org/10.1007/s40264-014-0213-4

Zobrazit plný text záznamu

Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials

Autor: Tjerk W. A. de Bruin, Andrew Wang, Kathrin Herrmann, Ming Zhou

Publikováno v: Clinical Diabetes and Endocrinology

Background This report evaluated the cardiovascular safety of the amylin analog pramlintide—an existing diabetes injectable treatment—by comparing relevant cardiovascular adverse events (AEs) reported in previous phase 3 and 4 clinical trials amo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a810b9cfc0c13bd35d1dc454217e7670
https://pubmed.ncbi.nlm.nih.gov/28702246

Zobrazit plný text záznamu

Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension

Autor: Jennifer Sugg, Tjerk W. A. de Bruin, Lawrence A. Leiter, Shamik Parikh, Ingrid Gause-Nilsson, William T. Cefalu

Publikováno v: Journal of the American Geriatrics Society. 62(7)

Objectives: To assess the efficacy of dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, for the treatment of individuals with type 2 diabetes mellitus (T2DM) and preexisting cardiovascular disease (CVD). Design: Randomized, double-blind, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1581897e2cd4ab2e6ae3948b66441a1
https://pubmed.ncbi.nlm.nih.gov/24890683

Zobrazit plný text záznamu

Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome

Autor: Marleen M J, van Greevenbroek, Vicky M M-J, Vermeulen, Tjerk W A, de Bruin

Publikováno v: Journal of lipid research. 43(11)

The aim of this study was to evaluate whether soluble factors in plasma of familial combined hyperlipidemia (FCHL) patients affect hepatic protein secretion. Cultured human hepatocytes, i.e., HepG2 cells, were incubated with fasting plasma (20%, v/v,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e2748975dc4861a53cf3287d05785983
https://pubmed.ncbi.nlm.nih.gov/12401883

Zobrazit plný text záznamu

Identification of differentially expressed genes in subcutaneous adipose tissue from subjects with familial combined hyperlipidemia

Autor: Petra M H, Eurlings, Carla J H, Van Der Kallen, Jan M W, Geurts, Paul, Kouwenberg, Willy D, Boeckx, Tjerk W A, De Bruin

Publikováno v: Journal of lipid research. 43(6)

Subjects with familial combined hyperlipidemia (FCHL) are characterized by a complex metabolic phenotype with hyperlipidemia, insulin resistance, and central obesity. FCHL is due to impaired adipose tissue function superimposed on hepatic overproduct

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fc571b5b125cd151b38aa615fddb1431
https://pubmed.ncbi.nlm.nih.gov/12032168

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání